These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 7553946)
1. [Paroxetine in the treatment of depressive disorders (pilot study)]. Svestka J; Novotný V; Kamenická V; Obrovská V; Cesková E Cesk Psychiatr; 1995 Jul; 91(3):135-42. PubMed ID: 7553946 [TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [TBL] [Abstract][Full Text] [Related]
3. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599 [TBL] [Abstract][Full Text] [Related]
4. A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Szegedi A; Wetzel H; Angersbach D; Dunbar GC; Schwarze H; Philipp M; Benkert O Pharmacopsychiatry; 1997 May; 30(3):97-105. PubMed ID: 9211571 [TBL] [Abstract][Full Text] [Related]
5. [The status of fluvoxamine among the antidepressive agents]. Svestka J; Cesková E; Rysánek R; Obrovská V; Kamenická V Cesk Psychiatr; 1992 Sep; 88(5):209-19. PubMed ID: 1451197 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Wade A; Crawford GM; Angus M; Wilson R; Hamilton L Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891 [TBL] [Abstract][Full Text] [Related]
7. Paroxetine in depressed adolescents with intellectual disability: an open label study. Masi G; Marcheschi M; Pfanner P J Intellect Disabil Res; 1997 Jun; 41 ( Pt 3)():268-72. PubMed ID: 9219077 [TBL] [Abstract][Full Text] [Related]
8. [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression]. Möslinger-Gehmayr R; Zaninelli R; Contu A; Oberhoff C; Gutschow K; Schindler AE; Staab HJ Zentralbl Gynakol; 2000; 122(4):195-202. PubMed ID: 10795116 [TBL] [Abstract][Full Text] [Related]
9. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708 [TBL] [Abstract][Full Text] [Related]
10. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Baldwin DS; Hawley CJ; Abed RT; Maragakis BP; Cox J; Buckingham SA; Pover GH; Ascher A J Clin Psychiatry; 1996; 57 Suppl 2():46-52. PubMed ID: 8626363 [TBL] [Abstract][Full Text] [Related]
11. Toxic epidermal necrolysis after paroxetine treatment. Ahmed R; Eagleton C N Z Med J; 2008 May; 121(1274):86-9. PubMed ID: 18535650 [TBL] [Abstract][Full Text] [Related]
12. [Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCl hemihydrate]. Vergouwen AC; Bakker A Ned Tijdschr Geneeskd; 2002 Apr; 146(17):811-2. PubMed ID: 12014241 [TBL] [Abstract][Full Text] [Related]
13. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072 [TBL] [Abstract][Full Text] [Related]
14. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence]. Daléry J; Aubin V Encephale; 2001; 27(1):71-81. PubMed ID: 11294041 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643 [TBL] [Abstract][Full Text] [Related]
16. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Baldwin D; Bridgman K; Buis C J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325 [TBL] [Abstract][Full Text] [Related]
17. Withdrawal after discontinuation of paroxetine. Arya DK Aust N Z J Psychiatry; 1996 Oct; 30(5):702. PubMed ID: 8902183 [No Abstract] [Full Text] [Related]
18. [Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine]. Schöne W; Ludwig M Fortschr Neurol Psychiatr; 1994 Sep; 62 Suppl 1():16-8. PubMed ID: 7959520 [TBL] [Abstract][Full Text] [Related]
19. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619 [TBL] [Abstract][Full Text] [Related]
20. Fluoxetine once every third day in the treatment of major depressive disorder. Tural U; Onder E Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]